Amsbio has reached agreement with Sanguine BioSciences to distribute and support its products and services throughout Europe.
Phillip Pridham-Field of Amsbio said of the agreement: “Sanguine’s approach to biospecimen collection and their high patient retention allow researchers to collect the data they need with better turnaround time and with the potential for longitudinal studies. We believe their extensive biospecimen library will be an excellent addition to our current product offerings for researchers in life sciences.”
Sanguine collects and de-identifies biospecimen, medical history and other data from patients diagnosed with severe and chronic diseases for use in biomarker research.
Researchers traditionally obtain biospecimen through hospitals, but this process often proves inefficient.
By connecting directly with patients, Sanguine is able to meet the needs of researchers and offer timely turnaround of biospecimen and medical data with diverse ranges for age, race, disease state, gender and treatments underway.
The patient engagement tactics used by the company have led to a 95% retention rate, which also allow for follow-up draws for longitudinal studies.
“There is no denying that personalised medicine has become a significant area of interest for drug discovery, but there exists a gap between researchers who require biospecimen respective medical data, and patients who want to be a part of research efforts,” said Brian Neman, founder and chief executive officer of Sanguine.
“We have engaged hundreds of patient subjects, and built a library of specimen and data that can effectively bridge this gap. We look forward to partnering with Amsbio to make this service accessible to researchers around the world working in different therapeutic areas,” he added.